Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
110 results about "Human papillomavirus types" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
(HPV) (hyū'măn pap'i-lō'mă-vī'rŭs) DNA virus of the genus Papillomavirus; certain types cause cutaneous and genital warts in humans, including verruca vulgaris and condyloma acuminatum; other types are associated with severe cervical intraepithelial neoplasia and anogenital and laryngeal carcinomas.
SgRNA combined with immunogene to inhibit high risk HPV expression, gene knockout vector thereof, and application of sgRNA and vector
ActiveCN105821040AImprove targetingGrowth inhibitionOrganic active ingredientsGenetic material ingredientsWilms' tumorCas9
The invention provides an sgRNA combined with immunogene to inhibit high risk HPV expression, a gene knockout vector thereof, and an application of the sgRNA and the vector. The sgRNA sequences of a human papilloma virus 16 type gene suitable for CRISPR-Cas9 targeting editing and a human PD-1 gene are selected, and the plasmid vector of the sgRNA and a CRISPR-Cas9 nuclease gene expression vector are transferred to HPV16+ human cervical carcinoma cells and HPV16+ transplantation tumor-bearing mice, and can obviously inhibit HPV16 expression and inhibit tumor growth. The gene expression vector prepared in the invention has the advantages of simple method steps, good sgRNA targeting property, high CRISPR-Cas9 knockout efficiency, accurate targeting splicing of high risk HPV16 type and PD-1 genes, efficient reduction of the expression of the high risk HPV16 type gene, and obvious inhibition of the tumor growth through combined application.
Owner:李旭
Shorten human papilloma virus 16 type L1 protein
Owner:XIAMEN INNOVAX BIOTECH +1
Fusion protein for inhibiting cervical cancer
ActiveUS7378100B2Carcinoma levelPrevent cancerPeptide/protein ingredientsVirus peptidesNucleotideProtein translocation
A fusion protein for inhibiting cervical cancer is disclosed, which comprises a peptide sequence of human papillomavirus type 16, a peptide translocating peptide for translocation, and a peptide within a carboxyl terminal fragment. The present invention further comprising a composition of antibody, which conjugates to E7 peptide, wherein the nucleotide sequence corresponding to the amino acid sequence of the E7 peptide is shown as SEQ. ID. NO.1.
Owner:THEVAX GENETICS VACCINE
Truncated l1 protein of human papillomavirus type 11
ActiveUS20100291141A1Reduced expression levelLow costVirus peptidesAntiviralsVirus-like particleAlphapapillomavirus
The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.
Owner:XIAMEN INNOVAX BIOTECH +1
Truncated l1 protein of human papillomavirus type 16
ActiveUS20100255031A1Difficult to applyReduced expression levelBacteriaPeptide/protein ingredientsVirus-like particleCervical cancer
The invention relates to a truncated L1 protein of the Human Papillomavirus Type 16, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of cervical cancer.
Owner:XIAMEN UNIV +1
Vaccine for chimeric virus-like particles and preparation method thereof
ActiveCN102153656AStrong immune-inducing activityInactivation/attenuationAntiviralsEpitopeChimerin Proteins
The invention discloses chimeric protein. The chimeric protein is obtained by inserting an epitope E7 of a human papillomavirus type 16 at a ring position of human papillomavirus type 16 (HPV 16) protein L1, namely between the 140th amino acid and the 141st amino acid, wherein the epitope E7 of the human papillomavirus type 16 has genes of protein (a) with the following codes: the protein is formed by an amino acid sequence shown by an MLDLQPETT epitope (12-20E7 for short), a RAHYNIVTF epitope(49-57E7 for short), an LLMGTLGIV epitope (82-90E7 for short) or a TLGIVCPI epitope (86-93E7 for short). The invention also discloses virus-like particles formed by aggregating the chimeric protein, a mixture formed by the virus-like particles and application of the virus-like particles and the mixture of the virus-like particles to the preparation of the vaccine for HPV 16 L1-virus-like particles.
Owner:SOUTH CHINA UNITED VACCINE INST
6,11 type human papillomavirus fluorescence quantitative PCR detection method and kit thereof
InactiveCN101676408AHigh sensitivityStrong specificityMicrobiological testing/measurementDNA/RNA fragmentationFluorescenceMicrobiology
The invention relates to a 6,11 type human papillomavirus fluorescence quantitative PCR detection method and kit thereof and PCR amplification primer and probe sequence for 6,11 type nucleotide segments of human papillomavirus. The primer sequence comprises: primer pair of human papillomavirus 6,11 type general upstream primer and general downstream primer, upstream primer complementation sequenceor downstream primer complementation sequence, also comprises primer sequences obtained in range of upstream primer extending towards 5'end by 10 basic groups and the upstream primer extending towards 3'end and 5'end by 10 basic groups. The probe sequence comprises: fluorescent probe: SEQ ID NO:3 and its complementation sequence, and probe sequence obtained in range of the extending SEQ ID NO:3 and its complementation sequence towards 3'end and 5'end by 10 basic groups. The method is used for quantitative detection of 6,11 type human papillomavirus with real clinical application value.
Owner:YANGTZE RIVER PHARMA GRP BEIJING HAIYAN PHARMA
HPV6 type l2n120e7e6 fusion protein gene, expression vector, method, bacterial strain and application
The invention provides a gene for encoding HPV (human papilloma virus) 6-type L2N120E7E6 fusion protein, expression vectors, a method, a bacteria strain and an application. The invention is characterized in that prokaryotic expression vectors are utilized to fuse HPV 6-type L2N-end 120 amino acids, E7 proteins and E6 proteins, and constructing the encoded gene according to the amino acid of the fusion protein. In the invention, the gene for encoding the HPV 6-type L2N120E7E6 fusion proteins is successfully designed and the expression vectors and the transformation bacteria strain of the high-expression HPV 6-type L2N120E7E6 fusion proteins are successfully constructed; and in the fusion proteins, the immunogenicity is strong, the immunoreaction of specific T cells can be induced, the tumor forming time of mice can be obviously delayed, and the growth of the tumors of 20% mice is completely restrained. The invention can be used for preventing and treating HPV 6-type infection and relevant diseases, such as genital wart.
Owner:中国疾病预防控制中心病毒病预防控制所
Human papillomavirus type bivalent virus-like particle mixed protein antigen and construction method
InactiveCN1683010AImproving immunogenicityImprove responseAntiviralsRecombinant DNA-technologyVaccine ImmunogenicityIndividual animal
The present invention relates to human papillomavirus type bivalent virus-like particle mixture, and human papillomavirus type bivalent virus-like particle mixing protein antigen and its construction method. The present invention includes one kind of cervical carcinoma virus HPV16 L1 antigen and one kind of condyloma acuminata virus HPV11 L1 antigen. The HPV11 L1 gene is first cloned from condyloma acuminata tissue through molecular geological method, and both HPV16 L1 gene cloned from cervical carcinoma tissue and the HPV11 L1 gene are then expressed in the insect cell expression system of baculovirus, so as to constitute recombinant virus strain Bacmid / HPV16-HPV11L1. Animal immunizing test shows that the constituted recombinant protein has excellent immunogenicity and immunoreactivity, and may be used as candidate antigen of gene engineering multivalent vaccine for preventing condyloma acuminata and cervical carcinoma.
Owner:HARBIN MEDICAL UNIVERSITY
Production of papillomavirus capsid protein and virus-like particles
ActiveUS8062642B1High expressionPeptide/protein ingredientsViral antigen ingredientsBaculovirus expressionVirus-like particle
The present invention is directed to a method of expressing the papillomavirus capsid protein coding sequence in a cell using an expression system under conditions facilitating expression of the protein in the cell.In another aspect of the invention, it has been discovered that virus-like particle(s) (VLPs), fragment(s), capsomer(s) or portion(s) thereof are formed from the papillomavirus capsid protein. It was further discovered that the virus-like particle(s) comprises antigenic characteristics similar to those of native infectious papillomavirus particles.In an embodiment of the invention, there is provided a method of expressing the L1 major capsid protein of human papillomavirus type-11 (HPV-11) in Sf-9 insect cells using the baculovirus expression system, and the production of HPV-11 virus-like particles.
Owner:UNIVERSITY OF ROCHESTER
Human papilloma virus (HPV) fusion protein, gene, carrier, strain, preparation method and application
The invention relates to a codon-optimized gene of a 16-type L2E7 recombinant protein of human papilloma virus (HPV), which can be expressed efficiently in colibacillus. The optimized gene can be expressed efficiently by being inserted in a prokaryotic expression vector pET9a, and the expression level accounts for 50% of all viruses; an expression protein is immune to mice after being purified. Proved by experiment results, the protein has the same immunogenicity with a protein which is not expressed by the optimized gene and can induce the release of specific gamma-1NF; proved by tumor growth inhibition animal experiments, protein immunity has evident inhibition effect on tumor growth and the growth of 90% of mouse tumor cells can be inhibited completely. The prokaryotic high-efficiency expression system of L2E7 recombinant protein, which is established by the optimized gene, can be used in the pilot scale production and drug discovery of preventive and curative vaccines of HPV16 infection and relevant cervical carcinoma.
Owner:中国疾病预防控制中心病毒病预防控制所
Truncated l1 protein of human papillomavirus type 58
ActiveUS20130315943A1Little conformational differenceReduced expression levelBacteriaPeptide/protein ingredientsDiseaseVirus-like particle
Provided are an N-terminal truncated L1 protein of the Human Papillomavirus Type 58, a coding sequence and preparation method thereof, and a virus-like particle comprising the protein. Uses of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine are further provided. The pharmaceutical composition or vaccine is used for prevention of HPV infection and a disease caused by HPV infection.
Owner:XIAMEN UNIV +1
Truncated l1 protein of human papillomavirus type 18
ActiveUS20100272751A1Reduced expression levelLow costProtozoaVirus peptidesVirus-like particleAlphapapillomavirus
The invention relates to a truncated L1 protein of the Human Papillomavirus Type 18, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of cervical cancer.
Owner:XIAMEN INNOVAX BIOTECH +1
Recombinant human papilloma virus type 33 L1 protein and its purpose
The invention provides a polynucleotides gene fragment of recombinant human papilloma virus type 33 L1 protein, a carrier containing the gene fragment, a host cell containing the comprise, and a HPV33L1 protein pentamer expressed by the gene fragment and an anti-HPV type 33 infection vaccine composed of the pentamer.
Owner:BEIJING HEALTH GUARD BIOTECH
Recombinant human papilloma virus 16L1 protein and its use
The invention relates to a recombinant human papilloma virus 16L1 protein and its use, and provides a new polynucleotides gene fragment coding the recombinant HPV16L1 protein, a vector containing the gene fragment, a host cell containing the vector, an HPV16L1 protein pentamer expressed by the gene fragment in translation, and an anti-HPV16 infection cervical carcinoma vaccine composed of the pentamer.
Owner:BEIJING HEALTH GUARD BIOTECH
A method for detection of human papillomavirus (HPV) type
Owner:ALLUM JENKINS
Virus-like particles of capsid proteins from human papillomavirus type 16/58/18/6/11 and the method for preparation and the uses thereof
ActiveUS20120107350A1Shorten the lengthSimplifying the complexity of the starting areaAnimal cellsSugar derivativesDiseaseTGE VACCINE
Five optimized genes of capsid L1 protein from human papillomavirus type 16, 58, 18, 6 and 11, which are modified by using insect's preferred codons and so on. Method for modifying those genes to express more highly in insect cells. Virus-like particle's vaccine compositions comprising HPV L1 proteins or their functional relatives produced by using those modified genes. Those optimized genes of L1 can be used to produce HPV 16 VLP, HPV 58VLP, HPV 18VLP, HPV 6 VLP, HPV 11VLP in insect cells. Yields of virus-like particles derived from those optimized HPV L1 genes are high. Mixed multivalent vaccines comprising above optimized HPV L1 genes can be used to prevent and treat multiple HPV infection and diseases related with it.
Owner:CHANGCHUN ZHUOYI BIOLOGICAL CO LTD
Human papilloma virus 16 type E7 protein functional antagonist peptide and encoding gene and application thereof
The invention discloses an HPV 16 type E7 protein functional antagonist peptide and an encoding gene and an application thereof. The amino acid sequence of the HPV 16 type E7 protein functional antagonist peptide is shown in a sequence 1 in a sequence list. The HPV 16 type E7 protein is taken as the target protein, micromolecular short peptides which can be combined with the HPV 16 type E7 protein and is used for inhibiting the activity of combination between the HPV 16 type E7 protein and the pRb protein are screened to obtain a group of HPV 16 type E7 protein functional antagonist peptides with consistent sequences, and the HPV 16 type E7 protein functional antagonist peptides can be taken as the drug candidate for curing the cervical carcinoma induced by the HPV infection. The HPV 16 type E7 protein functional antagonist peptide has wide application value and broad market prospect in the preparation of the drug for curing the cervical carcinoma induced by the HPV infection.
Owner:SHENZHEN GRADUATE SCHOOL TSINGHUA UNIV
Vaccine antigen capable of inducing cross-reacting and neutralizing antibody againts high-risk-type human papillomavirus
ActiveUS20100183648A1High activityAntibody mimetics/scaffoldsViral antigen ingredientsEpitopeVaccine antigen
Disclosed is a vaccine antigen capable of inducing a cross-reacting and neutralizing antibody directed against a high-risk-type human papillomavirus. Specifically disclosed are: a chimeric protein comprising an L2-epitope of a human papillomavirus (HPV) type-16 inserted in a loop region of a human papillomavirus type-16 L1 protein; and a capsid which is an aggregate of the chimeric protein. The loop region to which the L2-epitope is to be inserted is located between an amino acid residue at position-430 and an amino acid residue at position-433. The L2-epitope has an amino acid sequence represented by any one of the following formulae: YKTCKQAGTCPPDIIPKVEG (SEQ ID NO: 2) (18-32 L2-epitope); GGLGIGTGSGTGGRTGYIPL (SEQ ID NO: 3) (56-75 L2-epitope); and DPVGPLDPSIVSLVEESSFI (SEQ ID NO: 4) (96-115 L2-epitope).
Owner:JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NAT INST OF INFECT IOUS DISEASES
Recombinant protein HPV6L1 (Human Papilloma Virus 6 L1) and application thereof
The invention provides a novel polynucleotide gene segment of coded recombinant protein HPV6L1, a vector containing the gene segment, a host cell containing the vector, a protein HPV6L1 pentamer obtained by translating and expressing the gene segment, and an HPV6 infection-resistant condyloma acuminate vaccine consisting of the pentame.
Owner:BEIJING HEALTH GUARD BIOTECH
Recombinant human papilloma virus 18L1 protein and its use
ActiveCN104045695AAvoid degradationImprove solubilityBacteriaViral antigen ingredientsPentamerPolynucleotide
The invention relates to a recombinant human papilloma virus 18L1 protein and its use, and provides a new polynucleotides gene fragment coding the recombinant HPV18L1 protein, a vector containing the gene fragment, a host cell containing the vector, an HPV18L1 protein pentamer expressed by the gene fragment in translation, and an anti-HPV18 infection condyloma acuminatum vaccine composed of the pentamer.
Owner:BEIJING HEALTH GUARD BIOTECH
Rapid and sensitive genotype identification and nucleic acid detection
InactiveCN105392896AMicrobiological testing/measurementOrgan movement/changes detectionDiseaseUreaplasma parvum
The invention discloses a method, primer, probe and kit for identifying various gene mutations or substance genetic typing. In one embodiment, the disease is pathogenic. In the other embodiment, the invention is applied to detection of multidrug-resistant Mycobacterium tuberculosis, hepatitis B virus, beta-globulin mutation, thrombophilia related mutation; or various sexually transmitted pathogens, consisting of Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma urealyticum, Ureaplasma parvum, Treponema pallidum, Herpes simplex virus 1 , Herpes simplex virus 2, Human papillomavirus type 6, and Human papillomavirus type 1.
Owner:DIAGCOR LIFE SCI LTD
Method for guiding expression of major capsid proteins L1 of HPV16 (human papilloma virus 16) in pichia pastoris by using formaldehyde dehydrogenase promoter
InactiveCN104593408ALow costMicroorganism based processesFermentationTGE VACCINEPapillomavirus Vaccines
The invention relates to a method for guiding the expression of major capsid proteins L1 of HPV16 (human papilloma virus 16) in pichia pastoris by using a formaldehyde dehydrogenase promoter, wherein the expression of major capsid proteins L1 of HPV16 is controlled by a pichia pastoris formaldehyde dehydrogenase promoter. The method disclosed by the invention mainly comprises the following steps: i) building a pichia pastoris expression vector guided by a pichia pastoris formaldehyde dehydrogenase promoter; and ii) under the guidance of the formaldehyde dehydrogenase promoter, expressing the major capsid proteins L1 of HPV16 in different carbon / nitrogen source combined culture media. According to the invention, based on a pichia pastoris expression system, and starting with the regulating characteristics of the formaldehyde dehydrogenase promoter, the optimized expression of major capsid proteins L1 of HPV16 is implemented in the different carbon / nitrogen source combined culture media according to the characteristics of the promoter, so that the efficient expression of the major capsid proteins L1 of HPV16 is realized, thereby obtaining a low-cost virus-like particle preparation technology and implementing the low-cost preparation of human papilloma virus vaccines.
Owner:INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
Rapid genotyping analysis and kits thereof
ActiveCN106906306AMicrobiological testing/measurementOrgan movement/changes detectionDiseaseMycobacterium tuberculosis
The present invention provides methods, primers, probes, and kits for identifying gene mutation or material genotyping. In one embodiment, the materials are disease-causing agents. In another embodiment, the present invention is applied to detecting multidrug-resistant mycobacterium tuberculosis, hepatitis B virus, beta-globulin mutation, thrombosis-related mutations; or multiple sexually transmitted diseases causing agents, including but not limited to, trichomonas vaginalis, chlamydia, neisseria gonorrhoeae, mycoplasma, mycoplasma hominis, ureaplasma urealyticum, Mycelia, Treponema pallidum, Herpes simplex virus type 1 and type 2 and human papilloma virus type 6 and type 11.
Owner:DIAGCOR LIFE SCI LTD
16 type human papilloma virus major capsid protein L1 gene
ActiveCN101440371AIncrease productionMeet the requirements of industrial productionFungiMicroorganism based processesProtein targetHuman papillomas virus
The invention provides an L1 major capsid protein gene of human papillomavirus type 16 and a pichia pastoris strain expressing the gene. The gene sequence of the L1 protein is the gene sequence which is optimized by codon preferred by pichia pastoris, and corrects the optimized codon frequency to express the L1 protein. The L1 major capsid protein gene of human papillomavirus type 16 is an optimized L1 gene, and has the advantages that the optimized gene is more suitable for high expressing target proteins in pichia pastoris host and can meet the requirement of industrial production; meanwhile, a pichia pastoris expression system is adopted, so the cost is low, the yield is high, and the product nature is more uniform and stable.
Owner:SHANGHAI ZERUN BIOTECHNOLOGY CO LTD
Construction scheme and use of recombinant adeno related virus containing 16 type HPV antisense E7 gene
InactiveCN101440378AAvoid formingPrevent proliferationGenetic material ingredientsMacromolecular non-active ingredientsFhit geneWilms' tumor
The invention discloses a proposal for constructing gland related virus containing 16 type antisense E7 gene of human papilomavirus(HPV), and particular application of a recombination gland related virus constructor obtained by the proposal in tumor treatment. By techniques of full length enlarging by the PCR method, enzyme cutting, connection, homologous recombination, transfection, purification of gland related virus and the like, the recombination gland related virus constructor is obtained. The technical characteristic comprises that a 16 type E7 gene cDNA segment of the full length exogenous HPV is oppositely inserted in a NotI enzyme cutting site. The recombination gland related virus constructor has the following obviously technical advantages: chromosomes can be integrated in a fixed site; the inserted reverse exogenous gene is a full length segment, and has good specificity; and the constructor has strong effect on cells infected with the 16 type HPV, and has prevention function. The recombination gland related virus constructor provides an ideal gene target point specificity treatment and prevention application way for treating and preventing tumor gene.
Owner:武汉市奥尼克斯基因技术有限公司
Codon-optimized HPV16LI for salmonella vaccine strains against human papillomavirus type 16
InactiveCN101115766AImproving immunogenicityImprove stabilityViral antigen ingredientsVirus peptidesAmpicillinKanamycin
The present invention relates to a novel nucleic acid sequence (HPV16 L1S) encoding antigenic HPV16 L1 protein as provided in SEQ ID NO: 1, wherein the sequence has atleast one modified codon for optimum stability of recombinant plasmid vector when transformed in the prokaryotic micro-organism for improved immunogenicity of the resulting prokaryotic micro-organism. The invention further relates to constructing recombinant vectors pFS14nsdHPV16L1 and pFS14nsdHPV16 kan L1S harboring SEQ ID NO: 1, wherein the former carries Ampicillin and the latter, Kanamycin as a selection marker. The invention also relates to an attenuated strain of a prokaryotic micro-organism transformed with nucleic acid encoding HPV16 (Human Papillomavirus) major capsid protein and expressing the corresponding protein. In addition the invention discloses a process of producing a vaccine based on prokaryotic micro-organism for the treatment of papillomavirus infection and associated risk of cancer.
Owner:INDIAN IMMUNOLOGICALS LIMITED
Polypeptide medicament for treating tumor caused by human papillomavirus type 18 or vaccine
InactiveCN101214369AEasy to store and transportFacilitate automated mass productionPeptide/protein ingredientsViral antigen ingredientsSide effectT lymphocyte
A polypeptide drug or bacterin for curing tumor caused by Human Papillomavirus Type 18 is characterized in that the aminophenol order is amido end- VAWDSVYYM- carboxyl end, which is a multi-copy serial structure with lysine as a joint and a plurality of aminophenol orders connected. The present invention has the advantages of convenient transport and storage as well as automatic mass production. The present invention also has the capacity of activating specific cytotoxic T lymphocytes (CTL) and the specific CTL cell can kill, damage and dissolve target cells with the relative tumor sign Human Papillomavirus Type 18. The present invention has obvious effect and no side effect.
Owner:THE THIRD AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIV OF PLA
A common type of human papillomavirus quadruple fluorescent quantitative PCR typing detection method
ActiveCN101709335BHigh detection sensitivityHigh detection throughputMicrobiological testing/measurementFluorescence/phosphorescenceClinical efficacyFluorescence
Owner:ZHEJIANG UNIV
Peptide antigen of human papillomavirus type 16 and application thereof
InactiveUS20070218080A1High activityPeptide/protein ingredientsViral antigen ingredientsPeptide antigenCytotoxicity
Disclosed is a HPV-16 peptide antigen, and the antigen comprises a peptide sequence of SEQ ID No: 1. The peptide antigen of the invention is able to bind with MHC class I antigen on the cell and be presented on the cell surface. It can be recognized by cytotoxic T lymphocytes (CTLs), therefore induces CTL responses for cytolysis to control the replication and expression of the HPV-16.
Owner:MACKAY MEMORIAL HOSPITAL
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com